Summary
Gilead Sciences, Inc. (GILD) has filed an 8-K report on February 10, 2026, announcing its financial results for the fourth quarter and full year ended December 31, 2025. The report primarily serves to disseminate this earnings information to investors. Investors should refer to Exhibit 99.1, the press release, for detailed financial performance, including both GAAP and non-GAAP measures. Management emphasizes that while non-GAAP information is provided for enhanced operational and financial planning insights, it is not a substitute for GAAP figures. A reconciliation of these non-GAAP measures to their GAAP equivalents is available within the press release. The filing itself is procedural, directing stakeholders to the comprehensive earnings announcement for substantive financial details and commentary.
Key Highlights
- 1Gilead Sciences announced financial results for Q4 and Full Year 2025 on February 10, 2026.
- 2The primary purpose of the 8-K is to provide investors with the company's earnings release (Exhibit 99.1).
- 3Financial results presented include both GAAP (Generally Accepted Accounting Principles) and non-GAAP measures.
- 4Management believes non-GAAP measures offer useful supplemental insights for investors, aiding in operational and financial planning.
- 5A reconciliation between GAAP and non-GAAP financial information is provided within the earnings press release.
- 6The filing includes the standard Cover Page Interactive Data File in its XBRL format.